Eyecare spin-off Bausch + Lomb files for IPO

Almost 18 months since its parent company announced Bausch + Lomb (B+L) would be spun off as a pure-play eye health company, the entity has filed for an initial public offering (IPO) on the New York and Toronto stock exchanges.
Read More
Can:Do 4Kids

Showing kids what they can do

Can:Do 4Kids aims to enable low vision children across all areas throughout their lives. The service works collaboratively with orthoptists to support clients and their families, writes TRACEY STUART.
Read More

How optometry is bouncing back

Specsavers data has quantified the impact of extended lockdowns on Victorian eye health for the first time. DR BEN ASHBY delves into the data, and explains why metropolitan Melbourne isn’t out of the woods yet. Read More

Finding a niche with preservative-free eye drops

In the space of 23 years AFT Pharmaceuticals has gone from a home-based business to a multinational company. Its eyecare business is also experiencing remarkable growth, and more therapies are in the pipeline, including one for glaucoma. Read More

Using Medicare to detect glaucoma

An additional 79,000 Australians are expected to develop glaucoma in the next five years, costing the economy $4.3 billion [1]. Specsavers optometry director DR BENJAMIN ASHBY explains some of the strategic initiatives, including OCT and visual fields, in place to mitigate this problem. Read More

Introducing the RANZCO president

From individual patients to national eyecare systems, Tasmanian ophthalmologist Professor Nitin Verma has made it his mission to improve visual outcomes in developing countries. Now he’s bringing his unique knowledge to the RANZCO presidency. Read More